159 related articles for article (PubMed ID: 25417177)
1. Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40.
Hu X; Li X; Zhao M; Gottesdiener A; Luo W; Paul S
Mol Neurodegener; 2014 Nov; 9():52. PubMed ID: 25417177
[TBL] [Abstract][Full Text] [Related]
2. Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models.
Lonskaya I; Hebron M; Chen W; Schachter J; Moussa C
Mol Neurodegener; 2014 Nov; 9():46. PubMed ID: 25384392
[TBL] [Abstract][Full Text] [Related]
3. Beta-amyloid 1-42 monomers, but not oligomers, produce PHF-like conformation of Tau protein.
Manassero G; Guglielmotto M; Zamfir R; Borghi R; Colombo L; Salmona M; Perry G; Odetti P; Arancio O; Tamagno E; Tabaton M
Aging Cell; 2016 Oct; 15(5):914-23. PubMed ID: 27406053
[TBL] [Abstract][Full Text] [Related]
4. Human amyloid β peptide and tau co-expression impairs behavior and causes specific gene expression changes in Caenorhabditis elegans.
Wang C; Saar V; Leung KL; Chen L; Wong G
Neurobiol Dis; 2018 Jan; 109(Pt A):88-101. PubMed ID: 28982592
[TBL] [Abstract][Full Text] [Related]
5. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease.
Folwell J; Cowan CM; Ubhi KK; Shiabh H; Newman TA; Shepherd D; Mudher A
Exp Neurol; 2010 Jun; 223(2):401-9. PubMed ID: 19782075
[TBL] [Abstract][Full Text] [Related]
6. Aβ1-6
Diomede L; Zanier ER; Moro F; Vegliante G; Colombo L; Russo L; Cagnotto A; Natale C; Xodo FM; De Luigi A; Mosconi M; Beeg M; Catania M; Rossi G; Tagliavini F; Di Fede G; Salmona M
Mol Psychiatry; 2023 Jun; 28(6):2433-2444. PubMed ID: 37198260
[TBL] [Abstract][Full Text] [Related]
7. Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease.
Iijima K; Gatt A; Iijima-Ando K
Hum Mol Genet; 2010 Aug; 19(15):2947-57. PubMed ID: 20466736
[TBL] [Abstract][Full Text] [Related]
8. Endoplasmic reticulum stress mediates JNK-dependent IRS-1 serine phosphorylation and results in Tau hyperphosphorylation in amyloid β oligomer-treated PC12 cells and primary neurons.
Zhang X; Tang S; Zhang Q; Shao W; Han X; Wang Y; Du Y
Gene; 2016 Aug; 587(2):183-93. PubMed ID: 27185631
[TBL] [Abstract][Full Text] [Related]
9. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
10. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
11. Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β.
Vossel KA; Xu JC; Fomenko V; Miyamoto T; Suberbielle E; Knox JA; Ho K; Kim DH; Yu GQ; Mucke L
J Cell Biol; 2015 May; 209(3):419-33. PubMed ID: 25963821
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
Chu J; Lauretti E; Craige CP; Praticò D
J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease.
Pérez M; Morán MA; Ferrer I; Avila J; Gómez-Ramos P
Acta Neuropathol; 2008 Oct; 116(4):409-18. PubMed ID: 18679696
[TBL] [Abstract][Full Text] [Related]
14. BACE1 RNA interference improves spatial memory and attenuates Aβ burden in a streptozotocin-induced tau hyperphosphorylated rat model.
Yu CJ; Liu W; Chen HY; Wang L; Zhang ZR
Cell Biochem Funct; 2014 Oct; 32(7):590-6. PubMed ID: 25230339
[TBL] [Abstract][Full Text] [Related]
15. Immunolesion-induced loss of cholinergic projection neurones promotes β-amyloidosis and tau hyperphosphorylation in the hippocampus of triple-transgenic mice.
Härtig W; Saul A; Kacza J; Grosche J; Goldhammer S; Michalski D; Wirths O
Neuropathol Appl Neurobiol; 2014 Feb; 40(2):106-20. PubMed ID: 23566195
[TBL] [Abstract][Full Text] [Related]
16. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
17. The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42.
Finder VH; Vodopivec I; Nitsch RM; Glockshuber R
J Mol Biol; 2010 Feb; 396(1):9-18. PubMed ID: 20026079
[TBL] [Abstract][Full Text] [Related]
18. Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease.
Saul A; Sprenger F; Bayer TA; Wirths O
Neurobiol Aging; 2013 Nov; 34(11):2564-73. PubMed ID: 23747045
[TBL] [Abstract][Full Text] [Related]
19. Protein twists and turns in Alzheimer disease.
Maudsley S; Mattson MP
Nat Med; 2006 Apr; 12(4):392-3. PubMed ID: 16598285
[No Abstract] [Full Text] [Related]
20. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease.
Oddo S; Caccamo A; Green KN; Liang K; Tran L; Chen Y; Leslie FM; LaFerla FM
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):3046-51. PubMed ID: 15705720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
